Allogene Therapeutics Inc (ALLO)
3.07
+0.10
(+3.37%)
USD |
NASDAQ |
May 03, 16:00
3.065
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Revenue (Quarterly): -0.044M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.044M |
| September 30, 2023 | 0.043M |
| June 30, 2023 | 0.044M |
| March 31, 2023 | 0.052M |
| December 31, 2022 | -0.04M |
| September 30, 2022 | 0.049M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.086M |
| March 31, 2022 | 0.061M |
| December 31, 2021 | 75.65M |
| September 30, 2021 | 0.049M |
| June 30, 2021 | 0.044M |
| March 31, 2021 | 38.34M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-0.044M
Minimum
Dec 2023
75.65M
Maximum
Dec 2021
9.528M
Average
0.049M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Agenus Inc | 83.80M |
| ANI Pharmaceuticals Inc | 131.65M |
| Vaxart Inc | 6.625M |
| aTyr Pharma Inc | -- |
| PAVmed Inc | 1.049M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -89.26M |
| Total Expenses (Quarterly) | 71.88M |
| EPS Diluted (Quarterly) | -0.54 |
| Enterprise Value | 70.42M |
| Earnings Yield | -69.06% |
| Normalized Earnings Yield | -69.06 |